The effect of minoxidil in improving renal function of patients with malignant hypertension. 1981

G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams

UI MeSH Term Description Entries
D006974 Hypertension, Malignant A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction. Malignant Hypertension
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007677 Kidney Function Tests Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine. Function Test, Kidney,Function Tests, Kidney,Kidney Function Test,Test, Kidney Function,Tests, Kidney Function
D008297 Male Males
D008914 Minoxidil A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371) Loniten,Regaine,Rogaine,U 10858
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams
October 1978, JAMA,
G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams
November 1980, Annals of internal medicine,
G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams
November 1980, Annals of internal medicine,
G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams
June 1981, Annals of internal medicine,
G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams
February 1983, Orvosi hetilap,
G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams
January 1980, Journal of cardiovascular pharmacology,
G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams
September 1989, Journal of clinical pharmacology,
G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams
January 1983, The Quarterly journal of medicine,
G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams
January 1980, Journal of cardiovascular pharmacology,
G A Alleyne, and R Douglas, and T E Forrester, and G A Grell, and A G Morgan, and G D Nicholson, and W Williams
October 1976, Journal of clinical pharmacology,
Copied contents to your clipboard!